from Reuters: Business News https://ift.tt/2yPohAN
Thursday, 8 August 2019
Sarepta says adverse event report for DMD gene therapy erroneously submitted
Sarepta Therapeutics Inc said on Thursday it was informed that an adverse event report was erroneously submitted to the U.S. health regulator regarding an ongoing study of the company's gene therapy for Duchenne muscular dystrophy (DMD).
from Reuters: Business News https://ift.tt/2yPohAN
from Reuters: Business News https://ift.tt/2yPohAN
Subscribe to:
Post Comments (Atom)
One chart helps explain why Elon Musk is axing Tesla's Model S and X
Tesla is giving the Model X the ax. Its sales have likely been in decline for a few years. Wang Gang/VCG via Getty Images Elon Musk sai...
-
Caroline Purser/Getty Images The S&P 500 has shed 4% since the beginning of the year as Big Tech stocks decline. However, previou...
-
AP Photo The Magnificent Seven stocks' dominance may soon fade, warns Glenmede Investment Management. Current market concentratio...
-
The Bell V-280 Valor was selected as the Army's future long-range assault aircraft in 2022. Photo courtesy of Bell The US Army desi...
No comments:
Post a Comment